AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24989831 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 360
Study 22156966 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable contraception
Number of subjects: 3354
Study 22156966 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 3354
Study 22156966 — intervention group
Group type: EXPERIMENTAL
Intervention: Condoms
Number of subjects: 3354
Study 22156966 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine devices, implantable methods, surgical sterilization
Number of subjects: 3354
Study 20554708 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg annually
Number of subjects: 7765
Study 20554708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7765
Study 18936231 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (240 mg)
Number of subjects: 36
Study 18936231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15797158 — intervention group
Group type: EXPERIMENTAL
Intervention: Short educational package on communication skills (commented video footage)
Number of subjects: 36
Study 15797158 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 36
Study 12579102 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g)
Number of subjects: 30
Study 12579102 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (180 mg)
Number of subjects: 30
Study 11310904 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol containing 0.005% EDTA (propofol EDTA)
Number of subjects: 210
Study 11310904 — intervention group
Group type: COMPARATOR
Intervention: Non-EDTA sedative agents
Number of subjects: 210
Study 11310904 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 210
Study 8612407 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted high-density lipoprotein preparation (2 mg/mL)
Number of subjects: 32
Study 8612407 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 age- and gender-matched subjects)
Number of subjects: 32
Study 8612407 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with infections
Number of subjects: 32
Study 8612407 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in the ICU
Number of subjects: 32
Study 8612407 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in the ICU over 8 days
Number of subjects: 32
Study 1348620 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.015 mg/kg (priming) followed by 0.285 mg/kg
Number of subjects: 30
Study 1348620 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.3 mg/kg (single dose)
Number of subjects: 30
Study 1348620 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.3 mg/kg (both groups)
Number of subjects: 30
Study 1348620 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.75 mg/kg for reversal
Number of subjects: 30
Study 2864943 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0
Study 2864943 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0
Study 2864943 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 0
Study 2864943 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium and Vecuronium
Number of subjects: 0
Study 2864943 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium and Pancuronium
Number of subjects: 0
Study 31145003 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral group support intervention
Number of subjects: 16
Study 29264780 — intervention group
Group type: EXPERIMENTAL
Intervention: LRYGB
Number of subjects: 33
Study 29264780 — intervention group
Group type: EXPERIMENTAL
Intervention: LSG
Number of subjects: 33
Study 26592200 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from carbamazepine (CBZ)
Number of subjects: 160
Study 26592200 — intervention group
Group type: COMPARATOR
Intervention: Non-withdrawal from carbamazepine (CBZ)
Number of subjects: 160
Study 24645671 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-enriched formula
Number of subjects: 207
Study 24645671 — intervention group
Group type: COMPARATOR
Intervention: Standard full-term formula
Number of subjects: 207
Study 23342412 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated albumin (GA) measurements
Number of subjects: 1211
Study 23342412 — intervention group
Group type: COMPARATOR
Intervention: Fasting plasma glucose (FPG)
Number of subjects: 1211
Study 23342412 — intervention group
Group type: COMPARATOR
Intervention: Haemoglobin A1c (HbA1c)
Number of subjects: 1211
Study 20415689 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 50 (BIAsp 50)
Number of subjects: 75
Study 20415689 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 70 (BIAsp 70)
Number of subjects: 75
Study 20415689 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BIAsp 50 and BIAsp 70
Number of subjects: 75
Study 19066382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 19066382 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.05 mg/kg
Number of subjects: 215
Study 19066382 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.15 mg/kg
Number of subjects: 215
Study 19066382 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg/kg
Number of subjects: 215
Study 19066382 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 215
Study 16029524 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive treatment
Number of subjects: 545
Study 16029524 — intervention group
Group type: COMPARATOR
Intervention: Early conservative treatment
Number of subjects: 545
Study 13129479 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid (MUFA)‐rich diet
Number of subjects: 8
Study 13129479 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acid (SFA)‐rich diet
Number of subjects: 8
Study 10647168 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization
Number of subjects: 120
Study 10647168 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization
Number of subjects: 120
Study 10647168 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific exercise
Number of subjects: 120
Study 10647168 — intervention group
Group type: EXPERIMENTAL
Intervention: Traction
Number of subjects: 120
Study 10647168 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy treatment based on classification
Number of subjects: 120
Study 10647168 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrater reliability of classification system
Number of subjects: 120
Study 8672379 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hyoscine
Number of subjects: 56
Study 8672379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 1341133 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml of a mixture including 3 ml of 0.5% bupivacaine, 1 ml fentanyl in 1 ml of 10% dextrose solution (Group II)
Number of subjects: 152
Study 1341133 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml of a mixture including 3 ml of 0.5% bupivacaine, 0.15 mg clonidine (Group IV)
Number of subjects: 152
Study 1341133 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml of 0.5% bupivacaine at 5 degrees C (Group VI)
Number of subjects: 152
Study 1341133 — intervention group
Group type: COMPARATOR
Intervention: 4 ml of 0.5% bupivacaine at 27 degrees C (Group I)
Number of subjects: 152
Study 1341133 — intervention group
Group type: COMPARATOR
Intervention: 4 ml of 0.5% bupivacaine at 20 degrees C (Group V)
Number of subjects: 152
Study 1341133 — intervention group
Group type: COMPARATOR
Intervention: 4 ml of a mixture including 3 ml of 0.5% bupivacaine, 0.20 mg adrenaline (Group III)
Number of subjects: 152
Study 4044828 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean men at rest after a 750-kcal mixed meal
Number of subjects: 16
Study 4044828 — intervention group
Group type: COMPARATOR
Intervention: Obese men at rest after a 750-kcal mixed meal
Number of subjects: 16
Study 4044828 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean men post exercise
Number of subjects: 16
Study 4044828 — intervention group
Group type: COMPARATOR
Intervention: Obese men post exercise
Number of subjects: 16
Study 4044828 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean men during exercise
Number of subjects: 16
Study 4044828 — intervention group
Group type: COMPARATOR
Intervention: Obese men during exercise
Number of subjects: 16
Study 30649836 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU day‐1 of vitamin D3
Number of subjects: 92
Study 30649836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 30303348 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental RF ablation (Venefit)
Number of subjects: 193
Study 30303348 — intervention group
Group type: COMPARATOR
Intervention: Monopolar RF ablation (EVRF)
Number of subjects: 193
Study 26553475 — intervention group
Group type: EXPERIMENTAL
Intervention: DUAL tDCS
Number of subjects: 20
Study 26553475 — intervention group
Group type: EXPERIMENTAL
Intervention: UNI tDCS
Number of subjects: 20
Study 26553475 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study 25311286 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience Triple P (RTP)
Number of subjects: 111
Study 25311286 — intervention group
Group type: COMPARATOR
Intervention: Assessment Control (AC)
Number of subjects: 111
Study 22357252 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m²) plus carboplatin (AUC5) followed by radiation (50.4 Gy) (arm-A)
Number of subjects: 263
Study 22357252 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous radiochemotherapy with cisplatin (40 mg/m²/week) (arm-B)
Number of subjects: 263
Study 22357252 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm-A (Paclitaxel and carboplatin)
Number of subjects: 263
Study 22357252 — intervention group
Group type: COMPARATOR
Intervention: Arm-B (Cisplatin)
Number of subjects: 263
Study 20693148 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosdex (Web-based PSA decision aid)
Number of subjects: 514
Study 20693148 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the text
Number of subjects: 514
Study 20693148 — intervention group
Group type: COMPARATOR
Intervention: Control group that completed the questionnaire
Number of subjects: 514
Study 20693148 — intervention group
Group type: COMPARATOR
Intervention: Control group that did not complete a questionnaire
Number of subjects: 514
Study 17397698 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) plus slow-release morphine
Number of subjects: 65
Study 17397698 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus slow-release morphine
Number of subjects: 65
Study 18557676 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute classroom activity on infant feeding
Number of subjects: 121
Study 18557676 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 121
Study 15191155 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg once daily
Number of subjects: 184
Study 15191155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 11747767 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic anastrozole tablet (1 mg)
Number of subjects: 20
Study 11747767 — intervention group
Group type: EXPERIMENTAL
Intervention: Imported anastrozole tablet (1 mg)
Number of subjects: 20
Study 9006702 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial graft tension of 20 N
Number of subjects: 70
Study 9006702 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial graft tension of 40 N
Number of subjects: 70
Study 9006702 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial graft tension of 80 N
Number of subjects: 70
Study 8422222 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (mean daily dose of 5.7 mg)
Number of subjects: 106
Study 8422222 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride (175 mg/d)
Number of subjects: 106
Study 8422222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 3312502 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (100 to 800 mg BID)
Number of subjects: 153
Study 3312502 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 to 320 mg)
Number of subjects: 153
Study 3312502 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol + Diuretic
Number of subjects: 153
Study 3312502 — intervention group
Group type: COMPARATOR
Intervention: Propranolol + Diuretic
Number of subjects: 153
Study 3312502 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 153
Study 3312502 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 153
Study 31615501 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic pain management during medical abortion
Number of subjects: 42
Study 31615501 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling about pain management before the abortion and support during the abortion process
Number of subjects: 42
Study 31615501 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management strategies discussed in pre-MA counseling
Number of subjects: 42
Study 27997236 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidirectional intervention (text messages with reproductive health information)
Number of subjects: 756
Study 27997236 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive intervention (text-messaging reproductive health quizzes)
Number of subjects: 756
Study 27997236 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidirectional intervention
Number of subjects: 756
Study 27997236 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive intervention
Number of subjects: 756
Study 27997236 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 756
Study 26153271 — intervention group
Group type: EXPERIMENTAL
Intervention: MPCs (rexlemestrocel-L) 0.3 × 10(6)/kg, n = 15
Number of subjects: 45
Study 26153271 — intervention group
Group type: EXPERIMENTAL
Intervention: MPCs (rexlemestrocel-L) 1.0 × 10(6)/kg, n = 15
Number of subjects: 45
Study 26153271 — intervention group
Group type: EXPERIMENTAL
Intervention: MPCs (rexlemestrocel-L) 2.0 × 10(6)/kg, n = 15
Number of subjects: 45
Study 26153271 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 16
Number of subjects: 45
Study 24347422 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting by operators with low annual in-trial volume (mean ≤3.2 procedures/y)
Number of subjects: 1546
Study 24347422 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting by operators with intermediate annual in-trial volume (3.2-5.6 procedures/y)
Number of subjects: 1546
Study 24347422 — intervention group
Group type: COMPARATOR
Intervention: Carotid artery stenting by operators with high annual in-trial volume (>5.6 procedures/y)
Number of subjects: 1546
Study 21823276 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Neiguan (PC 6)
Number of subjects: 40
Study 21823276 — intervention group
Group type: COMPARATOR
Intervention: Compound Danshen dripping pill (medicine group)
Number of subjects: 40
Study 19384788 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasospastic subjects
Number of subjects: 30
Study 19384788 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 19384788 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 17876407 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) on the right forearm to stimulate the extension of the index finger, 24 blocks for group 1 and 36 blocks for group 2.
Number of subjects: 45
Study 17876407 — intervention group
Group type: COMPARATOR
Intervention: Control group (submitted to 24 blocks of stimulation at a null intensity current).
Number of subjects: 45
Study 15736011 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 292
Study 15736011 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin plus rifampicin
Number of subjects: 292
Study 15736011 — intervention group
Group type: COMPARATOR
Intervention: Macrolides
Number of subjects: 292
Study 11986453 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc syrup
Number of subjects: 1792
Study 11986453 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc syrup and vitamin A
Number of subjects: 1792
Study 11986453 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc syrup (caretaker administered)
Number of subjects: 1792
Study 11986453 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 1792
Study 9809947 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent
Number of subjects: 116
Study 9809947 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 116
Study 7666102 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone plus granisetron (dexamethasone 8 mg IV + granisetron 3 mg IV)
Number of subjects: 428
Study 7666102 — intervention group
Group type: COMPARATOR
Intervention: Granisetron alone (3 mg IV)
Number of subjects: 428
Study 7666102 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone alone (8 mg IV)
Number of subjects: 428
Study 2548660 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (600 mg in 3 divided doses p.o.)
Number of subjects: 7
Study 2548660 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 7
Study 803997 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrogenated ergot alkaloids (DEA) (Hydergine)
Number of subjects: 53
Study 803997 — intervention group
Group type: COMPARATOR
Intervention: Papaverine
Number of subjects: 53
Study 31203240 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE-D web-based intervention
Number of subjects: 25
Study 31203240 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study 28038376 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps and hamstrings lean muscle volumes
Number of subjects: 20
Study 28038376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular fat fractions
Number of subjects: 20
Study 28038376 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh lean muscle mass
Number of subjects: 20
Study 28038376 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric strength
Number of subjects: 20
Study 26077235 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel
Number of subjects: 4954
Study 26077235 — intervention group
Group type: COMPARATOR
Intervention: Every-3-week paclitaxel
Number of subjects: 4954
Study 26077235 — intervention group
Group type: COMPARATOR
Intervention: Every-3-week docetaxel
Number of subjects: 4954
Study 26077235 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 4954
Study 23575450 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 80
Study 23575450 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 80
Study 22046702 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine (K)
Number of subjects: 45
Study 22046702 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (M)
Number of subjects: 45
Study 22046702 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam and ketamine combination (MK)
Number of subjects: 45
Study 19189403 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediagnostic IL-6 levels
Number of subjects: 0
Study 19189403 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 and BMI interaction
Number of subjects: 0
Study 19189403 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels
Number of subjects: 0
Study 19189403 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 genotype
Number of subjects: 0
Study 16798680 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental vocational counseling program
Number of subjects: 211
Study 16798680 — intervention group
Group type: COMPARATOR
Intervention: Standard vocational counseling program
Number of subjects: 211
Study 15677433 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 15677433 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics or risperidone
Number of subjects: 0
Study 11567048 — intervention group
Group type: EXPERIMENTAL
Intervention: TTR fibrils
Number of subjects: 16
Study 11567048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured neuronal‐like, Schwann, and endothelial cells incubated with TTR fibrils
Number of subjects: 16
Study 11567048 — intervention group
Group type: EXPERIMENTAL
Intervention: FAP nerves
Number of subjects: 16
Study 9129016 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐metHuSCF (5, 10, 15, or 20 microg/kg/d) plus Filgrastim (10 microg/kg/d)
Number of subjects: 38
Study 9129016 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (10 microg/kg/d) alone
Number of subjects: 38
Study 8198905 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% lignocaine 15 ml with adrenaline infiltrated into the proposed wound line 3 min before incision
Number of subjects: 90
Study 8198905 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 15 ml with adrenaline infiltrated into the wound on closure
Number of subjects: 90
Study 8198905 — intervention group
Group type: COMPARATOR
Intervention: No wound infiltration
Number of subjects: 90
Study 3297075 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study 3297075 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study 31420064 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (intramuscular regimen)
Number of subjects: 6018
Study 31420064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical regimen of normal saline)
Number of subjects: 6018
Study 24574052 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (LFX) 500 mg, once daily (o.d.)
Number of subjects: 65
Study 24574052 — intervention group
Group type: COMPARATOR
Intervention: Placebo, once daily (o.d.)
Number of subjects: 65
Study 23731579 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocker shoe designs with varying apex angle, apex position, and rocker angle
Number of subjects: 48